The mechanics of accretion/dilution
Accretion/dilution depends on the comparison between two rates: the earnings yield of the target (EPS ÷ acquisition price) and the cost of financing. If the acquirer uses stock, the relevant cost is its own earnings yield — if the target's earnings yield is higher than the acquirer's, the deal is accretive (buying a cheaper multiple with a more expensive one). If the acquirer uses debt, the relevant cost is the after-tax interest rate. If the target's earnings yield exceeds the after-tax cost of debt, the deal is accretive.
Why accretion doesn't equal value creation
This is the critical nuance. Suppose a company buys a target at a premium, using cheap debt. The deal is accretive because the earnings yield exceeds the after-tax cost of debt. But if the acquirer overpays — paying more than the present value of the synergies plus standalone target value — the deal destroys shareholder value despite being accretive. Conversely, a dilutive deal (common in all-stock acquisitions of fast-growing companies where the target's P/E is higher) can create substantial value if synergies or target growth more than justify the premium.
The correct framework: NPV of synergies
The value-creating test for an acquisition is: does the NPV of synergies (cost savings + revenue opportunities + financial synergies) exceed the premium paid? If a company pays £500M above the standalone value of the target, it must generate NPV synergies of at least £500M to break even for shareholders. This calculation should be done independently of accretion/dilution. The accretion test is a quick screen; the NPV test is the true measure of value creation.
Financing mix and deal structuring
The choice between cash, debt, and stock affects the accretion/dilution calculation differently. Cash deals are cleaner (no share count change) but require either cash on hand or debt financing. Debt-financed deals are typically accretive in low-rate environments. All-stock deals risk dilution but avoid cash outflow and share acquisition risk with the target's shareholders. Mixed consideration structures are common in large transactions. The optimal financing mix depends on: current leverage, the cost of debt vs. equity, the acquirer's currency (stock price), and tax efficiency.
"An accretive deal that destroys value is one of the most expensive mistakes in corporate finance — it looks good on the day of announcement and costs shareholders for years." — M&A advisory wisdom
What this means for you
When evaluating an M&A announcement, look beyond the accretion/dilution headline to the premium paid versus synergy guidance. A deal that is "1–2% accretive in year 2" on an optimistic synergy scenario with a 35% premium is almost certainly dilutive on a DCF basis unless synergies are extraordinarily certain. The best acquirers are those that consistently pay disciplined prices, capture their guided synergies, and deliver EPS accretion that is backed by real cash flow improvement — not financial engineering.